Mereo BioPharma Group plc

MREO

US5894921072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:56:45 17/07/2024 pm IST			5-day change	1st Jan Change
3.86 ^USD	-5.62%		+1.86%	+66.23%

16/07	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
09/07	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT

Mereo BioPharma Group plc Appoints Arun Mistry as Therapeutic Area Head, Setrusumab

September 17, 2019 at 04:30 pm IST

Mereo BioPharma Group plc announced the appointment of Dr. Arun Mistry as Therapeutic Area Head, Setrusumab.

Latest news about Mereo BioPharma Group plc

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	09/07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	26/06	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	24/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	21/06	MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Thursday Trading	20/06	MT
Leerink Partners Adjusts Price Target on Mereo BioPharma Group to $8 From $6, Maintains Outperform Rating	20/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	18/06	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
European Equities Close Lower Friday to End Rough Week of Trading	14/06	MT
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	14/06	MT
Mereo BioPharma Prices $50 Million Offering	14/06	MT
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	13/06	MT
Baird Initiates Mereo BioPharma Group With Outperform Rating, $8 Price Target	13/06	MT
Sector Update: Health Care Stocks Ease Late Afternoon	13/06	MT
Sector Update: Health Care	13/06	MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	12/06	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	12/06	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	12/06	MT
Sector Update: Health Care	12/06	MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	12/06	CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	12/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	10/06	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	07/06	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06	MT

Chart Mereo BioPharma Group plc

Duration

Period

More charts

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Sector

Biotechnology & Medical Research

Calendar

17/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mereo BioPharma Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.157 GBP

Average target price

5.656 GBP

Spread / Average Target

+79.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEREO BIOPHARMA GROUP PLC	+66.23%	624M
VERTEX PHARMACEUTICALS INCORPORATED	+20.23%	126B
REGENERON PHARMACEUTICALS, INC.	+22.74%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.88%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-13.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+10.05%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+51.66%	14.08B

Bio Therapeutic Drugs